Abstract
Elactocin is a novel anti-tumour antibiotic which has potent activity in vitro against a range of tumours. This phase I trial of elactocin identified the dose-limiting toxicity as profound anorexia and malaise. The schedules used included 1 h infusion 3 weekly, 24 h infusion 3 weekly, 1 h infusion daily x 5 (3 weekly), 1 h infusion weekly and finally continuous 5 day intravenous infusion. On all these schedules dose-limiting toxicity was the same and as no partial or complete responses were identified, we do not recommend that further trials of elactocin are performed.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Newlands, E., Rustin, G. & Brampton, M. Phase I trial of elactocin. Br J Cancer 74, 648–649 (1996). https://doi.org/10.1038/bjc.1996.415
Issue Date:
DOI: https://doi.org/10.1038/bjc.1996.415
This article is cited by
-
Targeting Nuclear Export Proteins in Multiple Myeloma Therapy
BioDrugs (2022)
-
XPO1/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor
Journal of Experimental & Clinical Cancer Research (2021)
-
Therapeutic strategies targeting FOXO transcription factors
Nature Reviews Drug Discovery (2021)
-
Selinexor decreases HIF-1α via inhibition of CRM1 in human osteosarcoma and hepatoma cells associated with an increased radiosensitivity
Journal of Cancer Research and Clinical Oncology (2021)
-
Decrease of 5-hydroxymethylcytosine and TET1 with nuclear exclusion of TET2 in small intestinal neuroendocrine tumors
BMC Cancer (2018)